Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNITE MCL
NCT06357676Phase 2Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2025
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, ibrutinib in mantle cell lymphoma (MCL), sponsored by OHSU Knight Cancer Institute. Started May 2025; status: recruiting.
02
Drugs
glofitamabibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06357676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06357676.